This clinical trial is focused on studying treatments for Moderate to Severe Crohn’s Disease, a condition that causes inflammation in the digestive tract, leading to symptoms like abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The study will explore the effects of several medications, including Lutikizumab (also known as ABT-981), ABBV-382, and Risankizumab (also referred to as ABBV-066). These medications are designed to target specific parts of the immune system to help reduce inflammation and manage symptoms.
The purpose of the study is to evaluate the safety and effectiveness of these targeted therapies. Participants will receive either one of the study medications or a placebo. The study will last for a period of up to 24 weeks, during which participants will receive regular treatments and undergo various health assessments to monitor their response to the medication. The goal is to see if these treatments can help achieve endoscopic remission, which means reducing the visible signs of inflammation in the digestive tract, and clinical remission, which involves a significant reduction in symptoms.
Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to gather information on how well the treatments work. This research aims to provide new insights into managing Crohn’s Disease and improving the quality of life for those affected by this condition.
1joining the study
Upon joining the study, you will be informed about the trial’s purpose, procedures, and potential risks and benefits. You will be asked to provide informed consent, which means you agree to participate after understanding all the details.
2initial assessment
An initial assessment will be conducted to confirm your eligibility. This includes verifying your age, weight, and medical history related to moderate to severe Crohn’s disease. A diagnosis of Crohn’s disease for at least three months prior to the start of the trial is required.
3baseline evaluation
A baseline evaluation will be performed to assess the current state of your condition. This may involve endoscopic procedures to check for mucosal inflammation and scoring systems to measure disease activity.
4treatment administration
You will receive one of the study medications, which may include lutikizumab, ABBV-382, or ABBV-066 (also known as risankizumab). These medications are administered as a solution for injection or infusion. The specific route and dosage will be determined by the study protocol.
5ongoing monitoring
Throughout the study, regular monitoring will occur to evaluate the safety and effectiveness of the treatment. This includes scheduled visits for health assessments and possibly additional endoscopic evaluations.
6end of treatment evaluation
At the end of the treatment period, an evaluation will be conducted to determine if the primary goal of endoscopic remission has been achieved. Secondary goals include assessing clinical remission based on symptom scores.
7follow-up
After completing the treatment phase, follow-up visits may be scheduled to monitor your health and any long-term effects of the treatment.
Who Can Join the Study?
Adults aged between 18 and 75 years old. You must also be of legal adult age according to local laws.
Your body weight must be at least 40 kg (about 88 pounds) at the start of the study.
You must have a confirmed diagnosis of Crohn’s Disease (CD) for at least 3 months before starting the study. This means you need to have biopsy results that show you have CD, as checked by the study doctor.
Your Crohn’s Disease Activity Index (CDAI) score must be 220 or higher at the start of the study. The CDAI is a way to measure how active your Crohn’s Disease is.
You need to have endoscopic evidence of mucosal inflammation. This means a doctor has looked inside your intestines and found inflammation. The inflammation score should be 6 or higher for disease in the ileocolonic or colonic area, or 4 or higher for disease only in the ileal area. These scores are determined by a specialist who reviews the images.
You must have shown intolerance or an inadequate response to one or more of the following types of drugs: oral locally acting steroids, systemic steroids (like prednisone), immunomodulators, or targeted therapies (TaTs).
Who Cannot Join the Study?
Patients with other serious health conditions that could interfere with the study.
Patients who have had a recent infection that required treatment with antibiotics.
Patients who have had a recent surgery or are planning to have surgery during the study period.
Patients who are currently participating in another clinical trial.
Patients who have a history of allergic reactions to the study medication or similar medications.
Patients who are pregnant or breastfeeding.
Patients who have a history of substance abuse or alcohol abuse.
Patients who have a history of cancer, except for certain types of skin cancer.
Patients who have a history of heart disease or uncontrolled high blood pressure.
Patients who have a history of liver or kidney disease.
Patients who have a history of blood disorders or bleeding problems.
Patients who have a history of mental health disorders that are not well controlled.
Patients who have received certain vaccines within a specific time frame before the study.
Patients who are unable to comply with the study procedures or follow-up visits.
Targeted Therapy A is a medication being studied for its potential to help people with moderate to severe Crohn’s Disease. This therapy is designed to specifically target certain pathways in the body that are believed to play a role in the inflammation and symptoms associated with Crohn’s Disease. By focusing on these pathways, the medication aims to reduce inflammation and improve the overall condition of patients.
Targeted Therapy B is another treatment option being explored in this clinical trial. Like Targeted Therapy A, it is intended to address specific mechanisms in the body that contribute to Crohn’s Disease. The goal of this therapy is to provide relief from the symptoms by targeting the underlying causes of inflammation, potentially leading to better management of the disease.
Targeted Therapy C is also part of the study, offering a different approach to treating Crohn’s Disease. This therapy works by interacting with particular biological processes that are thought to be involved in the disease’s progression. By doing so, it aims to decrease inflammation and help patients achieve a more stable and manageable condition.
Crohn’s Disease – Crohn’s Disease is a chronic inflammatory condition of the gastrointestinal tract, primarily affecting the small intestine and the beginning of the large intestine. It is characterized by inflammation that can penetrate deep into the layers of the bowel tissue, leading to symptoms such as persistent diarrhea, abdominal pain, and weight loss. The disease often progresses with periods of flare-ups and remission, where symptoms may subside or disappear. Over time, the inflammation can cause complications like strictures, fistulas, and malnutrition. The exact cause of Crohn’s Disease is unknown, but it is believed to involve a combination of genetic, environmental, and immune system factors. The progression and severity of the disease can vary significantly among individuals.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Austria 
Belgium 
Bulgaria 
Croatia 
Czechia 
Denmark 
Estonia 
Finland 
France 
Germany 
Hungary 
Ireland 
Italy 
Latvia 
Lithuania 
Norway 
Poland 
Portugal 
Romania 
Slovakia 
Slovenia 
Spain 
The Netherlands